Skip to content

US · TFX · MEDICAL - INSTRUMENTS & SUPPLIES

Teleflex Incorporated (TFX) intrinsic value and stock valuation

$161.58as of 2026-11-21 · Mkt cap 6.06B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Teleflex Incorporated DCF and intrinsic value

InvestorsCraft values TFX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TFX’s statements →

Teleflex Incorporated Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Wayne, PA 19087-1603 teleflex.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.99B-4.7% 5y CAGRd
20112025
Net income
-$-905.64M
20112025
Free cash flow
$245.4M-6.6% 5y CAGRd
20112025
Total equity
$3.12B-1.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.99B$3.05B$2.97B$2.79B$2.81B
Operating income$255.8M$151M$506.3M$499.7M$628.1M
Net income-$-905.64M$69.7M$356.3M$363.1M$485.4M
EPSd-$-20.25M$1.48M$7.53M$7.68M$10.2M
Operating cash flow$340.7M$635.7M$510.6M$342.1M$651.4M
Capital expenditure-$-95.24M-$-126.43M-$-91.44M-$-79.19M-$-71.62M
Free cash flow$245.4M$509.3M$419.2M$263M$579.8M
Total assets$6.95B$7.1B$7.53B$6.93B$6.87B
Total debt$2.73B$1.76B$1.93B$1.83B$1.97B
Net debt$2.33B$1.46B$1.7B$1.54B$1.52B
Total equity$3.12B$4.28B$4.44B$4.02B$3.75B
Cash and short-term investments$393.3M$306.2M$222.9M$292M$445.1M
Income statement
20252024202320222021
Revenue$1.99B$3.05B$2.97B$2.79B$2.81B
Cost of revenue$872M$1.34B$1.33B$1.26B$1.26B
Gross profit$1.12B$1.7B$1.65B$1.53B$1.55B
Research and development expenses$144.8M$161.7M$154.4M$153.8M$130.8M
Selling, general and administrative expenses$720.2M$995.3M$929.9M$863.8M$860.1M
Other expenses$0.00$394.7M$56.4M$13.8M-$-69.42M
Operating expenses$865M$1.55B$1.14B$1.03B$921.5M
Cost and expenses$1.74B$2.9B$2.47B$2.29B$2.18B
Interest income$6.4M$8.01M$12.8M$910K$1.33M
Interest expense$100.2M$83.5M$85.1M$54.3M$57M
Depreciation and amortization$177.7M$274.6M$242.1M$230.6M$237.4M
Ebitda$302.5M$433.6M$761.2M$730.8M$853.8M
Operating income$255.8M$151M$506.3M$499.7M$628.1M
Total other income/expenses, net-$-231.25M-$-75.53M-$-72.3M-$-53.81M-$-68.63M
Income before tax$24.6M$75.5M$434M$445.9M$559.5M
Income tax expense-$-33.98M$5.32M$76.4M$83M$74.4M
Net income-$-905.64M$69.7M$356.3M$363.1M$485.4M
Weighted average shares outstanding$44.6M$46.8M$47M$46.9M$46.8M
Weighted average diluted shares outstanding$44.7M$47.1M$47.3M$47.3M$47.4M
Balance sheet
20252024202320222021
Cash and short-term investments$393.3M$306.2M$222.9M$292M$445.1M
Net receivables$345.6M$459.5M$443.5M$408.8M$383.6M
Inventory$404.4M$600.1M$626.2M$578.5M$477.6M
Total current assets$1.94B$1.47B$1.41B$1.41B$1.43B
Property, plant and equipment, net$590.1M$611.8M$603.4M$578.4M$573.4M
Goodwill and intangible assets$3.83B$4.9B$5.42B$4.84B$4.79B
Long-term investments$11.2M$0.00$0.00$11.9M$0.00
Total non-current assets$5.01B$5.63B$6.13B$5.52B$5.44B
Total assets$6.95B$7.1B$7.53B$6.93B$6.87B
Accounts payable$130.2M$141M$132.3M$126.8M$118.2M
Short-term debt$100M$100M$87.5M$87.5M$110M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$762M$649.4M$606.8M$581.5M$680.1M
Long-term debt$2.63B$1.66B$1.84B$1.74B$1.86B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.06B$2.17B$2.48B$2.32B$2.44B
Capital lease obligations$84.2M$99.2M$111.3M$120.4M$116M
Total liabilities$3.82B$2.82B$3.09B$2.91B$3.12B
Common stock$48.2M$48.1M$48.1M$48M$47.9M
Retained earnings$3.15B$4.12B$4.11B$3.82B$3.52B
Accumulated other comprehensive income (loss)-$-239.47M-$-316.67M-$-314.4M-$-403.52M-$-346.96M
Total equity$3.12B$4.28B$4.44B$4.02B$3.75B
Total investments$11.2M$16M$0.00$11.9M$0.00
Total debt$2.73B$1.76B$1.93B$1.83B$1.97B
Net debt$2.33B$1.46B$1.7B$1.54B$1.52B
Cash flow statement
20252024202320222021
Net income$58.5M$69.7M$356.3M$363.1M$485.4M
Depreciation and amortization$177.7M$274.6M$242.1M$230.6M$237.4M
Stock-based compensation$0.00$31.4M$31.5M$27.2M$22.9M
Change in working capital-$-81.09M-$-1.82M-$-111.77M-$-239.96M$127.3M
Accounts receivable-$-85.53M-$-27.95M-$-15.76M-$-38.46M-$-600K
Inventory$84M$1.72M-$-41.07M-$-110.69M-$-11.14M
Accounts payable-$-8.28M$9.66M-$-31.26M-$-24.79M$94M
Net cash provided by operating activities$340.7M$635.7M$510.6M$342.1M$651.4M
Investments in property, plant and equipment-$-95.24M-$-126.43M-$-91.44M-$-79.19M-$-71.62M
Acquisitions, net-$-825.14M-$-120K-$-588.92M-$-186M$220.3M
Net cash used for investing activities-$-849.19M-$-99.36M-$-621.23M-$-257.94M$156.7M
Common stock issued$0.00$0.00$0.00$4.31M$11.1M
Common stock repurchased-$-300M-$-200M$0.00-$-4.31M$0.00
Dividends paid-$-60.27M-$-63.54M-$-63.9M-$-63.79M-$-63.65M
Net cash used for financing activities$611.5M-$-421.93M$38.5M-$-217.51M-$-715.82M
Net change in cash$73.7M$104.8M-$-69.19M-$-153.05M$69.2M
Cash at end of period$378.6M$327.7M$222.9M$292M$445.1M
Operating cash flow$340.7M$635.7M$510.6M$342.1M$651.4M
Capital expenditure-$-95.24M-$-126.43M-$-91.44M-$-79.19M-$-71.62M
Free cash flow$245.4M$509.3M$419.2M$263M$579.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Teleflex Incorporated

        Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

        CEO
        Jason Weidman
        Employees
        15.5K
        Beta
        0.82

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Teleflex Incorporated (TFX)?

        Teleflex Incorporated (TFX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TFX undervalued?

        TFX trades at a price of $161.58 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.